Skip to main content
Publications
Lacour JP, Khemis A, Giordano-Labadie F, Martin Lu, Staumont-Salle D, Hacard F, Tian H, McBride D, Hollis K , Hunter S, Martin L, Lamirand A, Le Guen S, Balp MM, Berard F. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study) . Eur J Dermatol. 2018 Dec 1. doi: 10.1684/ejd.2018.3446
Maurer M, Houghton K , Costa C, Dabove F, Ensina LF, Gimenez-Arnau A, Guillet G, Konstantinou GN, Labrador-Horrillo M, Lapeere H, Meshkova R, Pastorello E, Velasquez-Lopera M, Tamayo Quijano LM, Vestergaard C, Chapman-Rothe N. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study . World Allergy Organ J. 2018 Nov 16;11(32). doi: 10.1186/s40413-018-0216-1
Poulos C , Feldman SR, Gilloteau I, Boeri M, Guana A, Germino B, Boehm K, Gutknecht M, Augustin M. The most influential drivers of psoriasis patients' treatment choice: a discrete choice experiment survey in the US . Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Jia X, Zhao Y, Carrico J , Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.
Jia X, Zhao Y, Carrico J , Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.
Carrigan G, Whipple S, Capra WB, Taylor MD, Lu M, Arnieri B, Brown JS, Abernethy AP, Copping R, Rothman KJ . Potential for using external control arms derived from electronic health records to replace control arms from randomized controlled trials . Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(52):357. doi: 10.1002/pds.4629
Sussman G, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, Grattan C, Hollis K , Hunter S, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Maurer M, Nakonechna A, Ortiz De Frutos J, Reynolds M , Sweeney C , Tian H, Weller K, Wolin D , Balp MM. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU . Allergy. 2018 Aug;73(8):1724-34. doi: 10.1111/all.13430
Mease PJ, Gladman DD, Davenport EK , Zhou X , Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis . Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978
Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegard A, Berglind IA, Dedman D, Gutierrez L , Calingaert B , Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ , Perez-Gutthann S . Use of topical tacrolimus and topical pimecrolimus in four European countries: a multicentre database cohort study . Drugs Real World Outcomes. 2018 Jun;5(2):109-16. doi: 10.1007/s40801-018-0133-1
Maurer M, Houghton K , Berroa F, Ensina LF, Guillet G, Labrador M, Gimenez-Arnau AM, Marsland A, Rossi O, Velasco M, Chapman-Rothe N. Angioedema with and without wheals in patients with chronic spontaneous urticaria: findings from the worldwide prospective observational aware study . Presented at the EAACI Congress 2018; May 27, 2018. Munich, Germany.